4DMT unveils dose exploration data in wet AMD; Exicure installs new C-suite exec
4D Molecular Therapeutics has some new data from a Phase I/II trial testing a wet AMD candidate in different dose levels.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
